Experimental cell therapy targets Hard-to-Treat stage IV cancers
NCT ID NCT06296056
First seen Nov 01, 2025 · Last updated May 24, 2026 · Updated 24 times
Summary
This early-phase study tested a new combination of immune cells in 9 people with stage IV solid tumors that had stopped responding to standard treatments. The main goal was to check safety and side effects, while also looking for signs that the therapy might shrink or control the cancer. The approach aims to boost the body's own immune system to fight the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMORS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Seoul Hospital
Ulaanbaatar, Mongolia
Conditions
Explore the condition pages connected to this study.